Concorde Asset Management, LLC Dexcom Inc Transaction History

Concorde Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$94.08 - $130.2 $167,462 - $231,755	-1,780 Closed	0 $0
Q4 2021 Feb 02, 2022	BUY	$129.87 - $162.82 $1,168 - $1,465	9 Added 0.51%	1,780 $956,000
Q3 2021 Oct 21, 2021	BUY	$106.71 - $143.18 $188,983 - $253,571	1,771 New	1,771 $968,000
Q2 2021 Jul 20, 2021	SELL	$80.99 - $107.93 $74,348 - $99,079	-918 Closed	0 $0
Q1 2021 Apr 27, 2021	BUY	$84.79 - $104.74 $30,100 - $37,182	355 Added 63.06%	918 $330,000
Q4 2020 Jan 29, 2021	SELL	$78.0 - $104.5 $105,066 - $140,761	-1,347 Reduced 70.52%	563 $208,000
Q3 2020 Oct 23, 2020	BUY	$95.51 - $112.95 $182,424 - $215,734	1,910 New	1,910 $787,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Concorde Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Concorde Asset Management, LLC with notifications on news.